These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 18520303)
21. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib. Belani CP; Ramalingam S Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010 [No Abstract] [Full Text] [Related]
22. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271 [TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679 [TBL] [Abstract][Full Text] [Related]
25. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
26. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407 [TBL] [Abstract][Full Text] [Related]
27. Targeting resistance in lung cancer. Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718 [No Abstract] [Full Text] [Related]
28. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828 [TBL] [Abstract][Full Text] [Related]
29. K-ras mutations in non-small-cell lung carcinoma: a review. Aviel-Ronen S; Blackhall FH; Shepherd FA; Tsao MS Clin Lung Cancer; 2006 Jul; 8(1):30-8. PubMed ID: 16870043 [TBL] [Abstract][Full Text] [Related]
30. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467 [TBL] [Abstract][Full Text] [Related]
31. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Garassino MC; Marabese M; Rusconi P; Rulli E; Martelli O; Farina G; Scanni A; Broggini M Ann Oncol; 2011 Jan; 22(1):235-237. PubMed ID: 21169473 [No Abstract] [Full Text] [Related]
32. Ras oncogene mutations and survival in patients with lung cancer. Ferretti G; Felici A; Cognetti F Br J Cancer; 2006 May; 94(10):1548; author reply 1549. PubMed ID: 16641907 [No Abstract] [Full Text] [Related]
33. Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment. Deng S; Clowers MJ; Velasco WV; Ramos-Castaneda M; Moghaddam SJ Front Oncol; 2019; 9():1556. PubMed ID: 32039025 [TBL] [Abstract][Full Text] [Related]
34. Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells. Wang H; Lin Z; Nian Z; Zhang W; Liu W; Yan F; Xiao Z; Wang X; Zhang Z; Ma Z; Liu Z J Clin Invest; 2022 Sep; 132(17):. PubMed ID: 35819844 [TBL] [Abstract][Full Text] [Related]
35. Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells. Poku RA; Jones KJ; Van Baren M; Alan JK; Amissah F Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962236 [TBL] [Abstract][Full Text] [Related]
36. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620 [TBL] [Abstract][Full Text] [Related]
37. Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes. Stephens RM; Yi M; Kessing B; Nissley DV; McCormick F Cancer Inform; 2017; 16():1176935117711944. PubMed ID: 28634423 [TBL] [Abstract][Full Text] [Related]
38. Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells. Kim MH; Kim H J Cancer Prev; 2013 Sep; 18(3):221-6. PubMed ID: 25337549 [TBL] [Abstract][Full Text] [Related]
39. IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity. Bassères DS; Ebbs A; Cogswell PC; Baldwin AS Genes Cancer; 2014 Apr; 5(1-2):41-55. PubMed ID: 24955217 [TBL] [Abstract][Full Text] [Related]
40. Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy. Liclican EL; Walser TC; Hazra S; Krysan K; Park SJ; Pagano PC; Gardner BK; Larsen JE; Minna JD; Dubinett SM Cancer Prev Res (Phila); 2014 Aug; 7(8):845-55. PubMed ID: 24913817 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]